Connection
Mary Sammel to Lisdexamfetamine Dimesylate
This is a "connection" page, showing publications Mary Sammel has written about Lisdexamfetamine Dimesylate.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.342 |
|
|
|
-
Metcalf CA, Page CE, Stocker BOS, Johnson RL, Duffy KA, Sammel MD, Loughead J, Epperson CN. Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine. Gynecol Oncol. 2024 Nov; 190:62-69.
Score: 0.224
-
Epperson CN, Shanmugan S, Kim DR, Mathews S, Czarkowski KA, Bradley J, Appleby DH, Iannelli C, Sammel MD, Brown TE. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine. Psychopharmacology (Berl). 2015 Aug; 232(16):3091-100.
Score: 0.118